May 16, 2025

FDA Clears First Blood Test for Alzheimer’s

The FDA has cleared the first blood-based test to aid in diagnosing Alzheimer’s disease, offering a less invasive alternative to positron emission tomography scans and cerebrospinal fluid testing for cognitively impaired patients.

Conexiant

May 16, 2025

Long-Term Data Support BCT for BRCA-Mutated Breast Cancer

Researchers found that breast-conserving treatment provided long-term survival outcomes comparable to mastectomy in patients with breast cancer and BRCA1 or BRCA2 pathogenic variants.

Conexiant

May 15, 2025

First Migraine DHE Autoinjector FDA-Approved

FDA approves Brekiya®, a dihydroergotamine mesylate autoinjector for the acute treatment of migraine with or without aura and cluster headaches in adults.

Conexiant

May 15, 2025

Assistant Professor Salary Gaps Persist Nationwide

Persistent salary disparities by gender, race, and ethnicity were identified among more than 45,000 U.S. assistant professors, with underrepresented in medicine women learning the least across all specialties.

Conexiant

May 15, 2025

Medical Oddities: Mini Lab-Grown Ovaries Go Natural

Mini ovaries steal the show—plus heart cell choreography, Brussels sprout bias, and prenatal tea perks.

Conexiant

May 14, 2025

Leading Cause of Death in Residents, Study

Study shows high suicide rates during training transitions, with pathology residents facing the highest suicide risk compared with other specialties.

Conexiant

May 12, 2025

Prenatal Cannabis Use Tied to Adverse Birth Outcomes

Researchers report that prenatal cannabis use is associated with increased risks of low birth weight, preterm birth, and small for gestational age.

Conexiant

May 09, 2025

Early Psychosis Shows Four Suicide Risk Patterns

Researchers tracked suicidal behavior in early schizophrenia and found four distinct patterns linked to depression, delayed treatment, and childhood trauma.

Conexiant

May 09, 2025

Self-Harm Risk Rises Prior to and Following Gabapentinoids 

Researchers tracked over 10,000 patients and found the risk of self-harm was highest before starting gabapentinoids and again shortly after stopping, highlighting key periods for clinical monitoring.

Conexiant